16/05/2018 16:30:12

Bavarian Nordic to Host First Quarter 2018 Results Conference Call

Related content
11 Jul - 
Bavarian Nordic Announces Initiation of Phase 2 Trial E..
07 Jun - 
Bavarian Nordic A/S - Articles of Association
07 Jun - 
Capital Increase in Bavarian Nordic A/S as a Result of ..
Related debate
01:42 - 
Sure august
13 Jul - 
Dette er RSV og ikke kræft
13 Jul - 
Historisk er bavarian forsinket med op til 1 år hvad fo..

COPENHAGEN, Denmark -

May 16

, 201

8 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43

U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Jul
BAVA
En uge til 14 dage - vi har den 11/7 i dag, dvs der er gået godt fire uger... Gad vide hvad der ske..
8
10 Jul
BAVA
Porten, tak for dine dybe og nuancerede tråde... rart med skribenter der bringer noget til debatten ..
8
13 Jul
BAVA
Prostvac - selv om den ikke lykkes i mono terapi køre der uændret en masse fase to forsøg for at und..
4
11 Jul
BAVA
ENKOMMENTAR - 1000 Tak for seriøst bidrag, herligt med en sådan deling.   Jeg har lavet lidt noter u..
4
11 Jul
BAVA
@enkommentar; Det er forkert når du skriver, at "forsøg som har været afsluttet viser, at vaccinen h..
4
09 Jul
BAVA
Baron du er godt nok en være trold 😂😜😄
4
13 Jul
BAVA
Kik lige på vedlagte link https://www.clinicaltrials.gov/ct2/show/record/NCT02873286 Jeg kan ikke ..
3
12 Jul
BAVA
Den her gang er det som booster til GlaxoSmithKlines ebola vaccine hvor det før var Janssens   https..
2
11 Jul
BAVA
Bavarian Nordic offentliggør påbegyndelsen af fase 2 kombinationsforsøg med CV301 og nivolumab i met..
2
09 Jul
BAVA
bjoernesaks - Godt spørgsmål de kan begge vinde ... hvem som stiger mest eller mindst er svær at for..
2

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
CALI INVESTOR ALERT: Rosen Law Firm Reminds China Auto Logistics Inc. Investors of Important Deadline in First Filed Class Action  - CALI
2
EQUITY NOTICE: Rosen Law Firm Announces First Filed Class Action on behalf of Glencore plc Investors – GLNCY, GLCNF
3
CLASS ACTION UPDATE for QCOM and ORA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
4
COOL NOTICE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against PolarityTE, Inc.; Important Deadline – COOL
5
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PCG, UNM, and TAL

Related stock quotes

Bavarian Nordic A/S 192.50 -0.8% Stock price decreasing
Bavarian Nordic Ord Shs 192.50 -0.8% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2018 07:20:30
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB3 - 2018-07-16 08:20:30 - 2018-07-16 07:20:30 - 1000 - Website: OKAY